Medtronic Shares First Results from New Symplicity Spyral RDN Study
Medtronic announced the first results from the high cardiovascular risk cohort of its SPYRAL AFFIRM study, showcasing significant blood pressure reductions with its Symplicity Spyral renal denervation system.
The study, which completed enrollment, reported safe and sustained blood pressure reductions with no increase in anti-hypertensive medication use at six months, based on data from 210 patients at 59 sites across Europe, Australia, and the U.S.
The findings were shared at the 2025 Transcatheter Cardiovascular Therapeutics conference in San Francisco, adding to three-year Symplicity Spyral outcomes presented the previous day.
No increase in anti-hypertensive medication use at six months.Author's summary: Medtronic shares promising results from its SPYRAL study.
More News
- Lauri Markkanen first Jazz player to score 50 points since Karl Malone in win over Suns
- Art the Clown Owes One of His 'Terrifier' Actresses a Lot of Money
- New president of The Church of Jesus Christ of Latter-day Saints inherits a global faith far more diverse than many realize – Baptist News Global
- SKIMS’ chilling vision of the perfect female body
- From Reimagining Capitalism to Reweaving Ourselves: Leadership for a Sustainable and Caring Future in a World on Fire — Harvard ALI Social Impact Review
- Reimagining Nail Care: Turning Self-Care Into an Engine for Equity
- Mnangagwa delivers part of State of the Nation address in darkness after power outage – Nehanda Radio
- Gremsy Adds New NDAA Payloads with FLIR Thermal Technology
- Remains unearthed in Schenectady buried at local cemetery
- NGP-backed Cygnet Energy to buy Kiwetinohk Energy for $1bn | PE Hub